

---

# PRESS RELEASE



## For Immediate Release

**Contact:** info@globalcancertechnology.com

### **GLOBAL CANCER TECHNOLOGY INITIATES TRIPLE NEGATIVE BREAST CANCER PRECLINICAL STUDY WITH BAYLOR UNIVERSITY**

#### ***GCT.GLIO.1, A PI3K SELECTIVE INHIBITOR HAS SHOWN EXCEPTIONAL RESULTS IN EARLY PRECLINICAL STUDIES***

**San Diego, CA, August 2, 2022** – Global Cancer Technology, Inc. announced today that it has reached an agreement with Baylor University to further explore and validate the initial successful results achieved with GCT. Glio.1, a PI3K inhibitor, when used in cell culture models of breast cancer, including triple negative breast cancer (TNBC)

“We are excited to be working with Dr. Leigh Greathouse and her team at Baylor University. Dr. Greathouse, who is an Associate Professor in the Department of Nutrition Sciences, is an expert in how nutrient environment and the gut microbiome can influence treatment outcomes in cancer and other diseases. She will be testing our compound GCT.Glio.1 on breast cancer growth, an approach based on our compound’s effects on the important PI3Kinase growth pathway, that may also be influenced by a nutrient environment” said M. Karen Newell Rogers, PhD-Chief Scientific consultant for Global Cancer Technology and a Professor and Immunologist at Texas A&M University.

“Baylor University looks forward to exploring the promise of GCT. Glio.1 when used for breast cancer” commented Leigh Greathouse, PhD, Associate Professor, Nutrition Sciences and Associate Professor of Biology at Baylor University.

“We are delighted with the exceptional preclinical study data our PI3K inhibitor drug has accumulated to date and look forward to further validation by Dr. Greathouse and her highly regarded scientific team,” said John Clark, the CEO of Global Cancer Technology. Mr. Clark further added, “this PI3K inhibitor drug has produced similar results in advanced glioblastoma preclinical studies, and we anticipate being in a phase I glioblastoma clinical trial once our preclinical studies have been completed.

*Global Cancer Technology is a non-revenue biopharma company that is currently raising investment capital to enter a glioblastoma Phase 1 clinical trial.*

---

*Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's most recent shareholder letter. There is no assurance any new products can be cleared for sale by the FDA or successfully commercialized.*